| Items 101 ~ 120 of 25664, Page 6 of 1284 |
| 101. |
Merck¡¯s KEYTRUDA¢ç (pembrolizumab) Significantly Improved Overall Survival (OS) Compared to Chemotherapy in Patients with Advanced Esophageal or Esophagogastric Junction Carcinoma Whose Tumors Express PD-L1 (CPS ¡Ã10) - 11/14/2018
MERCK |
| |
With Pivotal KEYNOTE-181 Trial Meeting Primary Endpoint of OS, KEYTRUDA Becomes the First Anti-PD-1 Therapy to Demonstrate a Survival Benefit for These Patients |
| 102. |
AMA President Outlines Efforts to Attack Dysfunction in Health Care - 11/14/2018
American Medical Association |
| 103. |
Newest Prediabetes Awareness Campaign by Nation¡¯s Medical Authorities Spreads the Word: 1 in 3 Americans Has Prediabetes, Learn Your Risk - 11/14/2018
Centers for Disease Control and Prevention |
| |
On World Diabetes Day 2018, the American Medical Association (AMA), the Centers for Disease Control and Prevention (CDC) and the Ad Council continue the fight against type 2 diabetes |
| 104. |
Prediabetes Campaign: 1 in 3 in U.S. Has Prediabetes, Learn Your Risk - 11/14/2018
American Medical Association |
| |
On World Diabetes Day 2018, the AMA, the CDC and the Ad Council continue the fight against type 2 diabetes. |
| 105. |
Abbott Recommends Rejection of Below-Market Mini-Tender Offer by Baker Mills LLC - 11/14/2018
Abbott |
| |
ABBOTT PARK, Ill., Nov. 14, 2018 /PRNewswire/ --?Abbott (NYSE: ABT) received notice of an unsolicited mini-tender offer by Baker Mills LLC (Baker Mills) to purchase up to 60,000 Abbott common shares, representing approximately 0.003 percent of the company''''s outstanding shares. Baker Mills'''' offer price of $57.00 per share in cash is approximately 22 percent lower than the $72.79 closing price of Abbott common shares on Nov. 9, 2018, the last closing price prior to commencement of the offer. |
| 106. |
Merck Begins Rolling Submission of Licensure Application for V920 (rVSV G-ZEBOV-GP) to U.S. Food and Drug Administration - 11/13/2018
MERCK |
| |
V920 is the Company's Investigational Vaccine for Ebola Zaire |
| 107. |
FDA warns StemGenex Biologic Laboratories LLC of illegally marketing an unapproved cellular product manufactured in a facility with significant manufacturing violations, putting patients at risk - 11/13/2018
U.S. FOOD & DRUG ADMINISTRATION |
| |
The U.S. Food and Drug Administration has warned StemGenex Biologic Laboratories LLC (StemGenex) of San Diego, Calif; its owner/manager Rita F. Alexander and laboratory and medical director Jenny R. Galloway, M.D. about marketing a purported stem cell product without FDA approval ... |
| 108. |
AMA Adopts New Policies at 2018 Interim Meeting - 11/13/2018
American Medical Association |
| |
Affirming the Medical Spectrum of Gender / Protecting the Integrity of Public Health Data Collection / Opposing the Detention of Migrant Children / Increased Access to Identification Cards for the Homeless Population / Increasing Patient Access to Sexual Assault Medical Forensic Examinations and Post-Exposure Prophylaxis (PEP) for HIV in Emergency Departments |
| 109. |
New AMA Policies Adopted on Final Day of 2018 Interim Meeting - 11/13/2018
American Medical Association |
| |
Protecting and Improving Access to Zero-dollar Preventive Care / Continued 9-1-1 Modernization and Implementation of Text-to-9-1-1 Service / Expanding Broadband and Wireless Connectivity / Sexual Assault Education and Prevention in Public Schools |
| 110. |
Medtronic Receives CE Mark Approval for the Valiant Navion(TM) Thoracic Stent Graft System - 11/13/2018
Medtronic |
| |
Lower-Profile Thoracic Endovascular Aortic Repair (TEVAR) Device Broadens Treatable Patient Population with Thoracic Aortic Disease |
| 111. |
Future Physicians Should Seek Training to Enhance Access to Rural Care - 11/13/2018
American Medical Association |
| |
The AMA encourages medical students and residents to seek training opportunities in public and population health to increase access to care in rural areas. |
| 112. |
AMA Policy Aimed at Preventing Medical Student and Physician Suicide - 11/13/2018
American Medical Association |
| |
The AMA adopted policy during its Interim Meeting aimed at identifying patterns that could predict and ultimately prevent suicide among physicians-in-training. |
| 113. |
AMA Adopts Policy to Bolster Firearm Background Checks - 11/13/2018
American Medical Association (AMA) |
| |
AMA calls on states to strengthen their reporting of mental health records to NICS to help prevent firearm injuries and deaths. |
| 114. |
AMA Expands Anti-tobacco Policies to Further Protect Youth - 11/13/2018
American Medical Association (AMA) |
| |
The AMA adopted policies encouraging the FDA to prohibit the use of flavoring agents in tobacco products, including electronic nicotine delivery systems. |
| 115. |
AMA Policy Supporting Survivors of LGBTQ Intimate Partner Violence - 11/13/2018
American Medical Association |
| |
The policy calls for physician awareness of IPV among LGBTQ patients, and funding for programs and services for survivors that do not discriminate against commu |
| 116. |
AMA Advocates for Transparency in Food Labeling and Packaging - 11/13/2018
American Medical Association (AMA) |
| |
The AMA urges the FDA to develop front-of-package warning labels for foods that are high in added sugars based on the established recommended daily value. |
| 117. |
AMA Adopts Ethical Guidance for Health Care Decisions Involving Minors - 11/12/2018
American Medical Association |
| |
Physicians at the AMA Interim Meeting approved a general framework to work with families to balance the child¡¯s interests with the scope of parental authority. |
| 118. |
AMA Policy on In-person Importation of Prescription Drugs from Canada - 11/12/2018
American Medical Association |
| |
Physicians at the Interim Meeting of the AMA adopted policy supporting in-person importation of prescription drugs from licensed Canadian pharmacies. |
| 119. |
AAOS on Potentially Misvalued Codes in 2019 Medicare Physician Fee Schedule - 11/12/2018
American Academy of Orthopaedic Surgeons |
| 120. |
FDA Accepts Regulatory Submission for LYNPARZA¢ç (olaparib) Maintenance Therapy in Newly-Diagnosed, BRCA-Mutated Advanced Ovarian Cancer and Grants Priority Review - 11/12/2018
MERCK |
| |
Approval Would Expand Use of AstraZeneca and Merck¡¯s LYNPARZA to These Patients in the First-Line Setting Following Platinum-Based Chemotherapy / First U.S. Regulatory Submission Acceptance for a PARP Inhibitor as a First-Line Maintenance Treatment for Certain Patients with Advanced Ovarian Cancer |
